The updates and results keep coming from AIM’s high-flyers, with an upgrade for one of our Stonking Small Cap opportunities and plenty of encouragement from others, including one of our Bonkers Bargains. Read on here to find out more. (Free to read)
Tristel: all eyes remain on FDA approval
Tristel (LON: TSTL), the highly rated manufacturer of infection prevention products, has reassured that underlying profits for the year ending 30 June 2021 will be a little better than previously estimated, although there is a complication.
An upturn in sales activity, combined with a gross margin maintained at 80% and tight control over operating costs, will translate into sales of £31m (2020: £31.7m), in line…
Sign up and read the full article
Register to continue reading our content.
Already a member? Login
Previous article Next article